Progress on methotrexate gene polymorphisms in allogeneic hematopoietic stem cell transplantation
10.3760/cma.j.issn.1673-4408.2023.08.008
- VernacularTitle:甲氨蝶呤基因多态性在异基因造血干细胞移植中的研究进展
- Author:
Qi JI
1
;
Yi DONG
;
Shaoyan HU
Author Information
1. 苏州大学附属儿童医院血液科 215000
- Keywords:
Methotrexate;
Allogeneic hematopoietic stem cell transplantation;
Gene polymorphisms
- From:
International Journal of Pediatrics
2023;50(8):534-538
- CountryChina
- Language:Chinese
-
Abstract:
Methotrexate(MTX)is one of the main drugs used to prevent graft-versus-host disease(GVHD)after hematopoietic stem cell transplantation, but it can cause a variety of adverse reactions, including severe mucositis, bone marrow suppression and hepatotoxicity.Studies on MTX gene polymorphisms mainly focused on the efficacy and complications of high-dose MTX therapy for various cancers, with relatively few studies on hematopoietic stem cell transplantation.From the perspective of allogeneic hematopoietic stem cell transplantation(allo-HSCT), this article provided a comprehensive review on the pharmacokinetics, complications, and prognosis with MTX gene polymorphisms in allo-HSCT patients, in order to provide clinical reference.
